Rapid-Acting Insulin Analogs ICD-10 / CPT Cheatsheet for Women

Why Coding Accuracy Matters for Women on Rapid-Acting Insulin

Correct ICD-10 and CPT coding is not just a billing formality. It determines whether your pharmacy claim is approved, whether your CGM supplies are covered, and whether your prior authorization goes through on the first try. Women with diabetes face layered complexity: type 1 diabetes affects roughly 5-10% of all diagnosed diabetes cases, gestational diabetes affects approximately 6-7% of all pregnancies in the United States, and PCOS-related insulin resistance may require prandial insulin coverage even before a formal type 2 diagnosis is established.

A single wrong code, such as using E11 (type 2) when the correct code is E10 (type 1), can trigger a denial for a biosimilar rapid-acting analog or delay insulin pump authorization by weeks.

The Five Rapid-Acting Analogs in Clinical Use

| Brand Name | Generic | FDA Approval | Onset | Peak | Duration | |---|---|---|---|---|---| | Humalog | insulin lispro | 1996 | 15 min | 30-90 min | 3-5 h | | NovoLog | insulin aspart | 2000 | 10-20 min | 40-50 min | 3-5 h | | Apidra | insulin glulisine | 2004 | 10-15 min | 55 min | 3-5 h | | Lyumjev | ultra-rapid lispro | 2020 | 11 min | 1 h | 4-6 h | | Fiasp | faster aspart | 2017 | 4 min | 1.5-2 h | 3-5 h |

FDA approvals and labeling for these analogs are available via the FDA drug database.

ICD-10 Diagnosis Code Cheatsheet

The correct ICD-10 code drives everything downstream. The table below covers the codes your prescriber or billing team will use most often when a rapid-acting insulin analog is prescribed.

Type 1 Diabetes Codes (E10.x)

Women with type 1 diabetes use the E10 category. Type 1 is an autoimmune condition with distinct pathophysiology from type 2, and payers audit E10 vs. E11 mismatches aggressively.

| ICD-10 Code | Description | Common Clinical Scenario | |---|---|---| | E10.9 | Type 1 DM without complications | Straightforward T1D, stable | | E10.649 | T1D with hypoglycemia, no coma | Post-meal hypoglycemia on lispro | | E10.65 | T1D with hyperglycemia | Persistent postprandial spikes | | E10.8 | T1D with other specified complications | Gastroparesis affecting timing | | E10.10 | T1D with ketoacidosis, no coma | Urgent/inpatient visits |

ICD-10-CM 2025 tabular for E10 is maintained by the CDC NCHS.

Type 2 Diabetes Codes (E11.x)

Most women initiating a rapid-acting analog for prandial coverage of type 2 diabetes will use codes from the E11 category. Using insulin does not automatically make the code E11.649. Match the code to the clinical state at the visit.

| ICD-10 Code | Description | Common Clinical Scenario | |---|---|---| | E11.9 | Type 2 DM without complications | Stable, no hypoglycemia documented | | E11.649 | T2D with hypoglycemia, no coma | Reactive hypoglycemia on lispro | | E11.65 | T2D with hyperglycemia | Postprandial excursions on basal alone | | E11.641 | T2D with hypoglycemia with coma | Inpatient/ER scenario | | E11.8 | T2D with other specified complications | Neuropathy, nephropathy in same visit | | E11.69 | T2D with other specified complication | Retinopathy requiring cross-coding |

ADA Standards of Care 2024 specifically addresses when to add prandial insulin in type 2 diabetes.

Gestational Diabetes and Pregnancy Codes (O24.x)

These codes are specific to pregnancy and are required any time a rapid-acting insulin is prescribed during gestation. Using E11 instead of O24 in a pregnant patient is a common billing error that delays authorization.

| ICD-10 Code | Description | Trimester Notes | |---|---|---| | O24.010 | Pre-existing T1D, first trimester | Use with E10.x as secondary | | O24.012 | Pre-existing T1D, third trimester | Insulin needs often spike 30-50% | | O24.110 | Pre-existing T2D, first trimester | Use with E11.x as secondary | | O24.112 | Pre-existing T2D, third trimester | High postprandial variability | | O24.414 | GDM, insulin-controlled, third trimester | Most common GDM billing code | | O24.419 | GDM, insulin-controlled, unspecified trimester | Use when trimester not documented |

ACOG Practice Bulletin 190 on gestational diabetes is the primary guideline for coding GDM.

PCOS and Insulin Resistance Codes

Women with PCOS often have significant insulin resistance. Rapid-acting insulin may be prescribed for coexisting type 2 diabetes or impaired glucose tolerance. PCOS affects an estimated 6-12% of reproductive-age women and is strongly associated with insulin resistance regardless of BMI.

| ICD-10 Code | Description | |---|---| | E28.2 | Polycystic ovarian syndrome (primary code) | | E11.65 | T2D with hyperglycemia (secondary if coexistent) | | R73.09 | Other abnormal glucose (impaired glucose tolerance) | | Z79.4 | Long-term (current) use of insulin (always add as secondary) |

ASRM and ESHRE PCOS guideline updates confirm insulin resistance as a core feature of PCOS pathophysiology.

The Z79.4 Code: Never Skip It

Z79.4 (long-term insulin use) is a secondary code that must accompany any E11 code when a type 2 patient uses insulin. Without it, some payers deny CGM coverage and rapid-acting analog prior authorizations. It does not apply to type 1 (E10 already implies insulin dependence) or to gestational diabetes O24.4x codes.

CPT Procedure Code Cheatsheet

CPT codes describe what was done during the encounter. For rapid-acting insulin prescribing, the codes fall into four functional groups: office visits, diabetes education, device initiation, and supply codes.

Office Visit / Evaluation and Management (E&M) Codes

| CPT Code | Description | Typical Use | |---|---|---| | 99202-99203 | New patient, low-moderate complexity | First visit, starting lispro | | 99212-99214 | Established patient, low-moderate complexity | Insulin dose adjustment visit | | 99215 | Established patient, high complexity | Multiple insulin types, comorbidities | | 99417 | Prolonged E&M service, per 15 min | Extended counseling on carb ratios |

AMA CPT guidelines for 2025 E&M coding are available through the AMA.

Diabetes Education and Training Codes

Insulin initiation almost always requires structured education. These CPT codes cover that separately from the E&M visit.

| CPT Code | Description | Notes | |---|---|---| | 98960 | Education and training, individual, 30 min | Initial injection technique | | 98961 | Education and training, group (2-8 patients), 30 min | Group class | | G0108 | DSMT individual, 30 min (Medicare) | Replaces 98960 for Medicare patients | | G0109 | DSMT group, 30 min (Medicare) | Replaces 98961 for Medicare patients |

CMS covers diabetes self-management training under specific conditions outlined in the Medicare Benefit Policy Manual.

Insulin Pump and CGM-Related CPT Codes

Many women on rapid-acting analogs use an insulin pump (CSII) or a CGM. These devices generate their own CPT codes that are billed alongside or instead of injection codes.

| CPT Code | Description | |---|---| | 95249 | Ambulatory CGM device placement and training, physician | | 95250 | Ambulatory CGM recording and interpretation, 72+ hours | | 95251 | Ambulatory CGM analysis, physician interpretation | | 99091 | Collection and interpretation of physiologic data (remote CGM review) | | 95044 | Insulin pump initiation and training, per hour |

CMS LCD L33822 covers CGM reimbursement criteria, including the requirement for type 1 or insulin-requiring type 2 diabetes.

HCPCS Supply Codes for the Pharmacy Benefit

These codes are used by pharmacies and DME suppliers, not office billers, but knowing them helps your patients understand their coverage letters.

| HCPCS Code | Drug | Notes | |---|---|---| | J1815 | Insulin, per 5 units (any formulation) | Used for administered insulin only | | S5550 | Insulin, insulin analog, 50 units | Pharmacy claims | | S5551 | Insulin, insulin analog, 150 units | Higher-volume pharmacy claims | | A9270 | Non-covered supply (payer-specific denial code) | Not a billable code |

FDA Orange Book entries for each brand are cross-referenced with HCPCS codes in the CMS Drug Payment Table.

Pregnancy, Lactation, and Contraception

Rapid-acting insulin analogs are the preferred prandial insulin during pregnancy. This section is mandatory reading if you are pregnant, trying to conceive, or postpartum.

Pregnancy Safety

Insulin does not cross the placenta in clinically meaningful amounts. Human insulin and its analogs are considered the standard of care for glycemic management in pregnancy. Insulin lispro has the most strong human pregnancy data of all analogs, with multiple studies showing no increase in congenital anomalies versus regular human insulin.

Insulin aspart has been studied in the INSIGHT trial, where no significant difference in maternal or neonatal outcomes was found between aspart and human insulin in type 1 pregnancy. Glulisine has less human pregnancy data and is generally used only when lispro or aspart are not tolerated.

Pregnancy categories were retired by the FDA in 2015, replaced by the Pregnancy and Lactation Labeling Rule (PLLR). Under PLLR, lispro and aspart labeling states: animal reproduction studies have shown no evidence of harm, and available human data do not suggest increased fetal risk.

FDA PLLR labeling for insulin lispro (Humalog) is available via accessdata.fda.gov.

Trimester-Specific Dosing Shifts

Insulin requirements change dramatically across trimesters:

• First trimester: Insulin sensitivity may increase, raising hypoglycemia risk. Lispro doses often decrease.
• Second trimester: Progressive placental hormone-driven insulin resistance begins.
• Third trimester: Total daily insulin requirements may be 50-100% higher than pre-pregnancy doses due to human placental lactogen and cortisol.
• Postpartum: Insulin needs drop sharply within hours of delivery. Women who required large rapid-acting doses antepartum may need immediate dose reduction to avoid severe hypoglycemia.

ACOG Practice Bulletin 201 on pregestational diabetes in pregnancy covers trimester-by-trimester insulin adjustment.

Lactation

Insulin does not transfer into breast milk in meaningful concentrations. No dose adjustment is required for breastfeeding, but hypoglycemia risk is elevated during nursing sessions due to glucose consumption by mammary glands. Eating a small carbohydrate snack before or during nursing sessions reduces this risk.

Contraception Note

Rapid-acting insulin analogs are not teratogens and do not require contraception as a prerequisite for prescribing. If a woman with diabetes is using an analog and not planning pregnancy, optimizing glycemic control before conception is strongly advised. Preconception HbA1c below 6.5% is associated with the lowest rates of major congenital malformations.

Sex-Specific Physiology and Life-Stage Dosing

Reproductive Years: The Menstrual Cycle Changes Your Insulin Needs

Women using rapid-acting insulin analogs should know that insulin sensitivity is not static across the menstrual cycle. During the follicular phase (roughly days 1-14), estrogen enhances insulin receptor sensitivity, and postprandial glucose excursions tend to be smaller.

During the luteal phase (days 14-28), progesterone blunts insulin sensitivity. Luteal-phase insulin resistance is a documented physiological phenomenon and can raise postprandial glucose by 10-30 mg/dL on the same carbohydrate load that was well-controlled the previous week. Many women benefit from increasing their insulin-to-carb ratio by 10-20% during the luteal phase.

Perimenopause and Menopause

Estrogen withdrawal during perimenopause increases insulin resistance. Postmenopausal women have significantly higher fasting and postprandial glucose levels than premenopausal women of similar weight, independent of age. Women transitioning through menopause often need upward dose titration of rapid-acting analogs even without dietary changes.

Menopausal hormone therapy (MHT) with estradiol may partially restore insulin sensitivity. A woman who starts transdermal estradiol may find her rapid-acting insulin doses need downward adjustment within weeks of initiating MHT.

PCOS Across Reproductive Life

Insulin resistance in PCOS is present in approximately 70% of women with PCOS regardless of weight. When a woman with PCOS progresses to type 2 diabetes and requires rapid-acting insulin, the underlying hyperinsulinemia may make titration erratic. Metformin is typically continued alongside insulin in this population to reduce total insulin dose requirements.

A practical framework for PCOS-specific rapid insulin titration:

1. Start at a conservative insulin-to-carb ratio (1 unit per 20g carbohydrate rather than the standard 1:15).
2. Reassess every two weeks using CGM-derived postprandial data rather than fingerstick alone.
3. Adjust the ratio during the luteal phase separately from the follicular phase.
4. If total daily dose exceeds 1.5 units/kg/day, investigate for concurrent insulin secretagogue or GLP-1 agonist addition.

Who This Treatment Is Right For and Who Should Reconsider

Women Who Benefit Most from Rapid-Acting Analogs

Rapid-acting analogs are the standard prandial insulin for:

• Women with type 1 diabetes at any life stage
• Women with type 2 diabetes who have failed basal insulin alone (HbA1c remains above 8% despite optimized basal) based on ADA 2024 Standards of Care guidance
• Pregnant women with GDM not controlled by diet and exercise alone, per ACOG Practice Bulletin 190
• Women using insulin pumps (CSII), where only rapid-acting analogs are loaded
• Postpartum women with type 1 or pre-existing type 2 diabetes resuming full insulin regimens

Women Who Need Special Caution

Some women should approach rapid-acting analog initiation with additional monitoring:

• Women with hypoglycemia unawareness: rapid onset of action makes missed meals especially dangerous. The DEVOTE trial in people with type 2 diabetes found that nocturnal hypoglycemia is associated with higher cardiovascular event rates, and the same physiology applies to severe postprandial hypoglycemia.
• Women with gastroparesis: delayed gastric emptying means the meal glucose peak is delayed past the analog's peak action window, causing early hypoglycemia then late hyperglycemia. Ultra-rapid lispro or faster aspart may worsen this mismatch. Post-meal dosing (injecting after eating rather than before) is an option studied in clinical practice guidelines from the American Diabetes Association.
• Women with eating disorders: the combination of variable intake and rapid-acting insulin carries meaningful hypoglycemia risk and requires multidisciplinary management.
• Women with renal impairment: reduced renal clearance of insulin analogs prolongs their duration of action, requiring dose reduction.

Prior Authorization: What Payers Require for Rapid-Acting Analogs

Prior authorization (PA) requests for rapid-acting analogs, especially the newer ultra-rapid formulations (Lyumjev, Fiasp), typically require:

1. Diagnosis code documentation: E10 or E11 with the correct complication subcode, plus Z79.4 for type 2.
2. Trial of a preferred analog: most commercial payers require documentation that lispro or aspart was trialed before approving glulisine or the ultra-rapid formulations.
3. Clinical justification for ultra-rapid: documentation of postprandial glucose excursions above 180 mg/dL despite standard rapid analogs, or documented gastroparesis.
4. Prescriber specialty or diabetes diagnosis duration: some payers require the prescribing clinician to be an endocrinologist or diabetes specialist.
5. CGM data: increasingly, payers ask for time-in-range data from CGM downloads to justify analog escalation. This is where CPT 99091 or 95251 becomes relevant to the PA record.

CMS coverage determination for insulin analogs under Part D is governed by the formulary exception process described in the Medicare Prescription Drug Benefit Manual.

A common PA mistake in women of reproductive age: failing to include O24.x codes for a pregnant patient whose claim is being processed under her non-pregnant baseline diagnosis. The payer's algorithm sees E11.9 and no O24 code, assumes a non-pregnant adult, and applies standard step-therapy rules that may deny the preferred analog.

Evidence Gaps in Women: What Is Extrapolated vs. Directly Studied

Women have been systematically under-represented in insulin pharmacokinetic trials. The core PK/PD data for lispro, aspart, and glulisine come predominantly from studies in non-pregnant adults, with a male-majority composition. Several specific gaps exist:

Sex differences in insulin absorption rate from subcutaneous tissue are documented. Women have a higher percentage of subcutaneous fat and lower dermal blood flow in certain injection sites, which may delay absorption compared to data from male-dominant trials. A study in Diabetes Care found that abdominal injection sites showed faster absorption than thigh in women, with a clinically meaningful difference in time-to-peak.

The luteal-phase insulin resistance data comes largely from small studies in women with type 1 diabetes. The 2015 review by Trout and Homko summarizes this evidence as suggestive but not conclusive at the level of randomized controlled data.

Ultra-rapid analogs (Lyumjev, Fiasp) have limited pregnancy-specific data. Their use in pregnancy is currently off-label and based on extrapolation from standard rapid-analog safety data. The FDA label for faster aspart (Fiasp) notes that data in pregnant women are insufficient to establish risk.

Postmenopausal PK data for rapid analogs is essentially absent from published trials. Clinicians adjust doses empirically based on CGM data rather than population PK models validated in this group.